+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Global Chlamydia Infection Diagnostics and Therapeutics Market: Rising Awareness among Healthcare Providers Bolster Uptake, finds TMR

Posted on Aug 23, 2017

The global chlamydia infection diagnostics and therapeutics market is fairly consolidated as the combined share of the top five vendors in the diagnostics segment exceeded 58% of the overall market while the leading companies in the therapeutics segment accounted a share for approximately 24% in 2016, Transparency Market Research (TMR). Despite the presence of several players, the global market features a low competitive rivalry among the players. A growing number of products approved by governmental regulatory agencies in various developing and developed economies has increasingly benefitted market players. Leading players opt for expansion of their operations in potential regional markets, in a move to capitalize on emerging lucrative avenues. In addition, they are actively offering product launches, engaging in collaborations, and making strategic acquisitions to consolidate their shares in various regions.

The global market for chlamydia infection diagnostics and therapeutics stood at US$1,195.5 mn in 2016 and is projected to rise at a CAGR of 6.0% from 2017 to 2025 to reach a valuation of US$2,002.2 mn in 2025.

Based on the diagnostics method available for chlamydia infection, the market is segmented into nucleic acid amplification tests (NAATs), direct fluorescent tests, and PCR. Of these, the segment of NAAT held the major share accounting of more than 69.8% in 2016. NAAT tests are approved by FDA and the demand for these sensitive diagnostic tests is driven by the rising prevalence of chlamydia. Regionally, North America market held the major share of 55.5% of the global infection diagnostics market and accounted for more than 44.5% of the infection therapeutics market in 2016.

chlamydia infection dignostics therapeutics market

Rising Incidence and Prevalence of Chlamydia Infection Boost Market

The rising incidence of chlamydia infection, expanding screening coverage, and the phenomena of more complete reporting, especially in developed nations, are crucial factors boosting the demand for infection therapeutics market. The growing number of academic research, vast rise in healthcare spending in developed and developing countries in screening for sexually-transmitted diseases, and the increasing prevalence of the infection are the key driving the global chlamydia infection diagnostics and therapeutics market. The noted risk of the infection among young men and women attributed to various biological factors has bolstered the demand for the infection diagnostics. In addition, the availability of more sensitive diagnostic tests has led to a growing number of reported cases of the infection.

The advent of advanced, efficacious therapeutics is a significant factor expected to boost the market. In addition, the nature of chlamydial infections being asymptomatic, particularly among women, has led to the demand for diagnostics and therapeutics to meet the demand of a burgeoning patient pool. The availability of a well-structured reimbursement policy from public and private health insurance firms and the rising awareness among young populations in developed nations, such as that in North America and Europe, has catalyzed the market growth.

Social Stigma Associated With Chlamydia Screening May Discourage Young Women

The social stigma associated with the screening of Chlamydia trachomatis causing Chlamydia, is evident in increased bullying and ostracism, which has resulted in several unreported cases, thereby hindering the market to an extent. This is a key factor that has discouraged young women in the age group of 16-25 and among those aged more than 25 years who are sexually active to undergo voluntary screening. Nevertheless, the prevalence of various co-morbidity factors among women, especially fatal ectopic pregnancy, has triggered the demand for the infection therapeutics and diagnostics. Furthermore, the growing resources available to support Chlamydia screenings is expected to boost the market.

The availability of advanced screening tests is likely to bolster their uptake in developing and developed regions. Furthermore, the rising commercialization of advanced products by top players and the rising awareness of Chlamydia trachomatis among women bodes well for the market.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Chlamydia Infection Diagnostics and Therapeutics Market (Product Type - Diagnostics (Nucleic Acid Amplification Tests (NAATs), Direct Fluorescent Tests, and PCR) and Therapeutics (Macrolides, Quinolones, Sulfonamides, Tetracycline, and Aminopenicillins); End User - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017–2025.”

The global chlamydia infection diagnostics and therapeutics market is segmented based on:

Product Type

  • Diagnostics
    • Nucleic Acid Amplification Tests (NAATs)
    • Direct Fluorescent Tests
    • PCR
  • Therapeutics
    • Macrolides
    • Quinolones
    • Sulfonamides
    • Tetracycline
    • Aminopenicillins

End User

  • Diagnostics
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Therapeutics
    • Hospital Pharmacies
    • Drugstores
    • Retail Pharmacies
    • Online Pharmacies

Geography

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of MEA

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Back To Top